A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy …
FA Shepherd, J Pereira, TE Ciuleanu… - Journal of Clinical …, 2004 - ascopubs.org
7022 Background: In phase II studies, erlotinib has shown single agent activity in a number
of tumor types, including NSCLC. NCIC CTG BR. 21 is a randomized, placebo-controlled …
of tumor types, including NSCLC. NCIC CTG BR. 21 is a randomized, placebo-controlled …
Erlotinib in previously treated non–small-cell lung cancer
FA Shepherd, J Rodrigues Pereira… - New England journal …, 2005 - Mass Medical Soc
Background We conducted a randomized, placebo-controlled, double-blind trial to
determine whether the epidermal growth factor receptor inhibitor erlotinib prolongs survival …
determine whether the epidermal growth factor receptor inhibitor erlotinib prolongs survival …
Erlotinib for frontline treatment of advanced non–small cell lung cancer: a phase II study
G Giaccone, M Gallegos Ruiz, T Le Chevalier… - Clinical Cancer …, 2006 - AACR
Purpose: Erlotinib has proven activity in pretreated patients with advanced non–small cell
lung cancer (NSCLC). We evaluated erlotinib in the frontline treatment of advanced NSCLC …
lung cancer (NSCLC). We evaluated erlotinib in the frontline treatment of advanced NSCLC …
Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non–small cell lung cancer after failure of at least one prior chemotherapy …
JR Johnson, M Cohen, R Sridhara, YF Chen… - Clinical Cancer …, 2005 - AACR
Abstract Purpose: To describe the Food and Drug Administration (FDA) review and approval
of erlotinib (Tarceva, OSI Pharmaceuticals, Melville, NY) for treatment of patients with locally …
of erlotinib (Tarceva, OSI Pharmaceuticals, Melville, NY) for treatment of patients with locally …
Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non–small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial
U Gatzemeier, A Pluzanska, A Szczesna… - Journal of Clinical …, 2007 - ascopubs.org
Purpose Erlotinib is a potent inhibitor of the epidermal growth factor receptor tyrosine kinase,
with single-agent antitumor activity. Preclinically, erlotinib enhanced the cytotoxicity of …
with single-agent antitumor activity. Preclinically, erlotinib enhanced the cytotoxicity of …
TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non–small-cell lung cancer
RS Herbst, D Prager, R Hermann… - Journal of clinical …, 2005 - ascopubs.org
Purpose Erlotinib is a potent reversible HER1/epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor with single-agent activity in patients with non–small-cell lung cancer …
tyrosine kinase inhibitor with single-agent activity in patients with non–small-cell lung cancer …
The Current Situation: Erlotinib (Tarceva®) and Gefitinib (Iressa®) in Non-Small Cell Lung Cancer
RL Comis - The oncologist, 2005 - academic.oup.com
Molecular targeted therapies, such as the epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors (TKIs), provide a different mechanism of action from chemotherapy and can …
kinase inhibitors (TKIs), provide a different mechanism of action from chemotherapy and can …
Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non–small-cell lung cancer and a performance status of 2
R Lilenbaum, R Axelrod, S Thomas… - Journal of Clinical …, 2008 - ascopubs.org
Purpose A multicenter randomized phase II trial to evaluate two treatment strategies in the
first-line management of advanced non–small-cell lung cancer (NSCLC) patients with a …
first-line management of advanced non–small-cell lung cancer (NSCLC) patients with a …
[HTML][HTML] Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study
M Reck, N van Zandwijk, C Gridelli, Z Baliko… - Journal of Thoracic …, 2010 - Elsevier
Introduction: Erlotinib is a small molecule inhibitor of epidermal growth factor receptor
tyrosine-kinase activity that has been shown to significantly increase survival for patients …
tyrosine-kinase activity that has been shown to significantly increase survival for patients …
A phase I/II study of weekly high‐dose erlotinib in previously treated patients with nonsmall cell lung cancer
DT Milton, CG Azzoli, RT Heelan… - … Journal of the …, 2006 - Wiley Online Library
BACKGROUND. Preclinical studies have suggested that erlotinib at high doses may inhibit
additional sites downstream of the epidermal growth factor receptor (EGFR), resulting in …
additional sites downstream of the epidermal growth factor receptor (EGFR), resulting in …
相关搜索
- lung cancer trial of erlotinib
- randomized phase trial of erlotinib
- lung cancer randomized phase
- lung cancer paclitaxel chemotherapy
- lung cancer combination with cisplatin
- erlotinib for treatment chemotherapy regimen
- standard chemotherapy in patients
- paclitaxel chemotherapy erlotinib hydrochloride
- approval summary chemotherapy regimen
- standard chemotherapy trial of erlotinib
- standard chemotherapy lung cancer
- performance status trial of erlotinib
- performance status lung cancer
- lung cancer erlotinib in combination
- lung cancer erlotinib hydrochloride
- lung cancer cisplatin and gemcitabine